← Back to Analyst Consensus 
ANIK Buy
Anika Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 8
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 6, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 30, 2026 | B. Riley Securities | maintain | Buy → Buy | — | 54% |
| Feb 27, 2026 | Barrington Research | maintain | Outperform → Outperform | $17 | 56% |
| Jan 9, 2026 | Barrington Research | maintain | Outperform → Outperform | $16 | 56% |
| Nov 6, 2025 | Barrington Research | maintain | Outperform → Outperform | $16 | 56% |
| Sep 23, 2025 | Barrington Research | maintain | Outperform → Outperform | $15 | 56% |
| Jul 31, 2025 | Barrington Research | maintain | Outperform → Outperform | $15 | 56% |
| May 12, 2025 | Barrington Research | maintain | Outperform → Outperform | $19 | 56% |
| Mar 13, 2025 | Barrington Research | maintain | Outperform → Outperform | $20 | 56% |
| Nov 1, 2024 | Barrington Research | maintain | Outperform → Outperform | $25 | 56% |
| Oct 22, 2024 | Barrington Research | maintain | Outperform → Outperform | $37 | 56% |
| Aug 9, 2024 | Barrington Research | maintain | Outperform → Outperform | $37 | 56% |
| May 29, 2024 | Stephens & Co. | reiterate | Equal-Weight → Equal-Weight | $24 | 54% |
| May 9, 2024 | Barrington Research | maintain | Outperform → Outperform | $37 | 56% |
| Mar 14, 2024 | Barrington Research | maintain | Outperform → Outperform | $37 | 56% |
| Mar 14, 2024 | Stephens & Co. | reiterate | Equal-Weight → Equal-Weight | $22 | 54% |
| Jan 3, 2024 | Barrington Research | maintain | Outperform → Outperform | $29 | 56% |
| Nov 3, 2023 | Barrington Research | maintain | Outperform → Outperform | $28 | 56% |
| Aug 14, 2023 | Barrington Research | upgrade | Market Perform → Outperform | $24 | 56% |
| Aug 10, 2023 | Stephens & Co. | maintain | Equal-Weight → Equal-Weight | $23 | 54% |
| May 31, 2023 | Stephens & Co. | reiterate | Equal-Weight → Equal-Weight | $28 | 54% |
| Apr 14, 2023 | Stephens & Co. | reiterate | — → Equal-Weight | $28 | 54% |
| Mar 7, 2023 | Barrington Research | downgrade | Outperform → Market Perform | $0 | 56% |
| Nov 9, 2022 | Barrington Research | upgrade | Market Perform → Outperform | $31 | 56% |
| Mar 9, 2022 | Stephens & Co. | downgrade | Overweight → Equal-Weight | $0 | 54% |
| Nov 16, 2021 | Stephens & Co. | initiate | — → Overweight | $55 | 54% |
| Jul 16, 2021 | UBS | initiate | — → Neutral | $46 | 54% |
| Dec 16, 2020 | Barrington Research | upgrade | Market Perform → Outperform | $43 | 56% |
| Jan 21, 2020 | Sidoti & Co. | upgrade | Neutral → Buy | $61 | 40% |
| Nov 5, 2019 | BWS Financial | initiate | — → Sell | $29 | 60% |
| Sep 23, 2019 | First Analysis | downgrade | Strong Buy → Outperform | $0 | — |
| Feb 22, 2019 | Sidoti & Co. | downgrade | Buy → Neutral | $41 | 40% |
| Jul 27, 2018 | Barrington Research | upgrade | Market Perform → Outperform | $0 | 56% |
| Jun 20, 2018 | First Analysis | downgrade | Overweight → Equal-Weight | $34 | — |
| May 4, 2018 | Barrington Research | upgrade | Market Perform → Outperform | $0 | 56% |
| Feb 23, 2018 | Barrington Research | downgrade | Outperform → Market Perform | $0 | 56% |
| Jan 24, 2018 | First Analysis | upgrade | Equal-Weight → Overweight | $0 | — |
| Apr 27, 2016 | Northland Capital Markets | downgrade | Outperform → Market Perform | $0 | 50% |
| Feb 26, 2016 | Northland Capital Markets | maintain | — → Outperform | $50 | 50% |
| Oct 12, 2015 | Barrington Research | initiate | — → Outperform | $0 | 56% |
| Aug 28, 2015 | First Analysis | initiate | — → Equal-Weight | $0 | — |
Price Target Trend
Apr 24, 2026 Oct 26, 2026
EPS Estimates
0y —
+1y —
+1q —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days